<DOC>
	<DOC>NCT02287610</DOC>
	<brief_summary>The overall objective of the study is to assess the effectiveness of switching from immediate-release prednisone (conventional) therapy to delayed-release prednisone (RAYOS) in patients with moderately to severely active Rheumatoid Arthritis (RA), managed according to standard of care in clinical practice settings.</brief_summary>
	<brief_title>A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Adult Rheumatoid Arthritis (RA) participants previously receiving immediate release prednisone were enrolled in the trial if they and their physicians both consented. Once entered, participant baseline data were captured and they were switched to delayed-release prednisone and followed for approximately 12 weeks.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Age ≥ 18 and in general good health (Investigator discretion) with a recent stable medical history other than related to RA disease activity RA diagnosis is ≥ 6 months according to ACR and/or EULAR classification criteria for diagnosis of active RA Morning stiffness duration of at least 45 minutes at study entry RA disease activity as defined by DAS28 of ≥ 3.2 at study entry Currently receiving conventional immediaterelease prednisone ≥ 2.5 milligram (mg) every morning and previously agreed to switch to RAYOS Willing and able to sign an Informed Consent Form (ICF) Patient is unwilling to participate in the noninterventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>RA</keyword>
	<keyword>Delayed-release prednisone</keyword>
	<keyword>Immediate-release prednisone</keyword>
	<keyword>Non-interventional</keyword>
</DOC>